Literature DB >> 24621872

Surfing the biomarker tsunami at JACC: heart failure.

James L Januzzi1, G Michael Felker2.   

Abstract

Entities:  

Keywords:  atrial fibrillation; heart failure; natriuretic peptides

Mesh：

Substances：

Year:  2013        PMID： 24621872     DOI： 10.1016/j.jchf.2013.03.007

Source DB:  PubMed          Journal:  JACC Heart Fail        ISSN： 2213-1779            Impact factor:   12.035


× No keyword cloud information.
  11 in total

1.  Insulin-Like Growth Factor-Binding Protein-7 as a Biomarker of Diastolic Dysfunction and Functional Capacity in Heart Failure With Preserved Ejection Fraction: Results From the RELAX Trial.

Authors:  Parul U Gandhi; Hanna K Gaggin; Margaret M Redfield; Horng H Chen; Susanna R Stevens; Kevin J Anstrom; Marc J Semigran; Peter Liu; James L Januzzi
Journal:  JACC Heart Fail       Date:  2016-10-12       Impact factor: 12.035

2.  Galectin-3 in heart failure with preserved ejection fraction. A RELAX trial substudy (Phosphodiesterase-5 Inhibition to Improve Clinical Status and Exercise Capacity in Diastolic Heart Failure).

Authors:  Omar F AbouEzzeddine; Phillip Haines; Susanna Stevens; Jose Nativi-Nicolau; G Michael Felker; Barry A Borlaug; Horng H Chen; Russell P Tracy; Eugene Braunwald; Margaret M Redfield
Journal:  JACC Heart Fail       Date:  2015-03       Impact factor: 12.035

Review 3.  Redefining the role of biomarkers in heart failure trials: expert consensus document.

Authors:  Frank Kramer; Hani N Sabbah; James J Januzzi; Faiez Zannad; J Peter van Tintelen; Erik B Schelbert; Raymond J Kim; Hendrik Milting; Richardus Vonk; Brien Neudeck; Richard Clark; Klaus Witte; Wilfried Dinh; Burkert Pieske; Javed Butler; Mihai Gheorghiade
Journal:  Heart Fail Rev       Date:  2017-05       Impact factor: 4.214

Review 4.  Clinical Phenotyping of Heart Failure with Biomarkers: Current and Future Perspectives.

Authors:  Vichai Senthong; Jennifer L Kirsop; W H Wilson Tang
Journal:  Curr Heart Fail Rep       Date:  2017-04

Review 5.  The Current and Potential Clinical Relevance of Heart Failure Biomarkers.

Authors:  Parul U Gandhi; Jeffrey M Testani; Tariq Ahmad
Journal:  Curr Heart Fail Rep       Date:  2015-10

6.  Circulating multimarker profile of patients with symptomatic heart failure supports enhanced fibrotic degradation and decreased angiogenesis.

Authors:  Kevin J Morine; Vikram Paruchuri; Xiaoying Qiao; Najwa Mohammad; Adam Mcgraw; Adil Yunis; Iris Jaffe; Navin K Kapur
Journal:  Biomarkers       Date:  2015-12-15       Impact factor: 2.658

Review 7.  Well-Known and Novel Serum Biomarkers for Risk Stratification of Patients with Non-ischemic Dilated Cardiomyopathy.

Authors:  Larisa Anghel; Radu Sascău; Ioana Mădălina Zota; Cristian Stătescu
Journal:  Int J Mol Sci       Date:  2021-05-26       Impact factor: 5.923

Review 8.  Biomarkers in heart failure with preserved ejection fraction.

Authors:  W C Meijers; A R van der Velde; R A de Boer
Journal:  Neth Heart J       Date:  2016-04       Impact factor: 2.380

9.  ST2 and Galectin-3: Ready for Prime Time?

Authors:  Wouter C Meijers; A Rogier van der Velde; Rudolf A de Boer
Journal:  EJIFCC       Date:  2016-08-01

10.  Endostatin a Potential Biomarker for Heart Failure with Preserved Ejection Fraction.

Authors:  Michael Coll Barroso; Philip Boehme; Frank Kramer; Thomas Mondritzki; Till Koehler; Jan-Erik Gülker; Martin Karoff; Wilfried Dinh
Journal:  Arq Bras Cardiol       Date:  2017-09-28       Impact factor: 2.000
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.